DENGUE HEMORRHAGIC FEVER BURDEN AND PREVENTION IN VIETNAM: EXPERT ASSESSMENT AND OPINION
Main Article Content
Abstract
Dengue is an infectious disease caused by the Dengue virus, transmitted from an infected person to a healthy individual through mosquito bites. In Vietnam, the disease occurs year-round, typically increasing during the rainy season, affecting both children and adults. Dengue can progress acutely, causing shock,
coagulation disorders, organs failure, life-threatening complications, and death.
In recent years, the outbreak of the disease has shown increasingly complex patterns both globally and in Vietnam. The number of recorded cases remains very high each year and continues to rise, with a significant number of cases going unreported. The epidemic cycle of Dengue outbreaks has changed due
to various factors, including the impact of climate change, urbanization, rising average temperatures, and increased domestic and international travel.
The Dengue vaccine - TAK-003 has been proven effective and safe through research that meets the standards of the World Health Organization. In Vietnam, this vaccine has been approved and is indicated for individuals aged 4 years and older.
Experts from the Vietnam Infectious Diseases Association have consensus on the burden of Dengue in Vietnam, the complexity of its epidemiology, and its increasing trend. The association recommends proactive prevention through Dengue vaccination (TAK-003) for individuals aged 4 years and older, without
requiring prior infection screening. They emphasize the importance of ensuring safe implementation while continuing to update and supplement data on the efficacy, effectiveness, and safety of the TAK-003 vaccine worldwide.
Article Details
Keywords
Dengue Hemorrhagic fever(DHF), prevention, expert assessment and opinion
References
2. World Health Organization. Global Dengue surveillance [Internet]. 2024 [cited 2024 Sep 24]. Available from: https://shiny.apps.io/global-Dengue-surveillance.
3. World Health Organization. WHO position paper on Dengue vaccines. May 2024. Available from: https://www.who.int/publications/i/item/who-position-paper-on-Dengue-vaccines-may-2024.
4. Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Alera MT, Sierra V, et al. Efficacy of a
tetravalent Dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395(10234):1423-1433.
5. Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, et al. Three-year efficacy and safety of Takeda’s Dengue vaccine candidate (TAK-003). Clin Infect Dis. 2021;75(1):107-117.
6. Bộ Y tế Việt Nam. Hướng dẫn chẩn đoán và điều trị sốt xuất huyết Dengue. Quyết định số 2760/QĐ- BYT. Hà Nội: Bộ Y tế; 2023.
7. Bộ Y tế Việt Nam. Hướng dẫn giám sát và phòng, chống bệnh sốt xuất huyết Dengue. Quyết định số 3711/QĐ-BYT. Hà Nội: Bộ Y tế; 2014.
8. Viện Vệ sinh Dịch tễ Trung ương. Giám sát và phòng chống côn trùng và động vật y học của một số bệnh phổ biến ở người. Hà Nội: Nhà xuất bản Y học; 2022.
9. Thông tin kê toa Qdenga được Bộ Y tế cấp phép ngày 14/05/2024. Available from: https://dichvucong.dav.gov.vn/congbothuoc.